Daniel Kruger

Daniel J. Kruger is a researcher focused on epidemiological and survey research concerning naturalistic psychedelic use and its public-health implications. His recent work examines how people who consume psychedelics outside clinical settings make decisions about treatment cost and non-hallucinogenic alternatives, where they obtain and whom they trust for psychedelic information, and how psychedelic experiences can influence subsequent substance-use trajectories. Kruger has contributed a series of retrospective and cross-sectional analyses exploring major life changes after psychedelic use, substitution or reduction in other substance use following psychedelic experiences, and distinctions between naturalistic use and structured clinical care.

Kruger’s contributions are primarily methodological and descriptive, emphasising large-sample survey methods to map patterns of use, attitudes, and reported outcomes among community samples. His work informs harm-reduction strategies, policy discussions about access and cost of psychedelic-assisted therapies, and the need for clearer information pathways for people using psychedelics outside formal treatment settings. By documenting user-reported benefits and risks in naturalistic contexts, Kruger’s research helps contextualise clinical trial findings within broader population-level behaviours and preferences.